Is AEON or CNTB more profitable?

AEON Biopharma's return on equity of 0.00% beat Connect Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets AEON Biopharma N/A N/A -994.63% Connect Biopharma N/A -165.41% -121.58%

Does the media prefer AEON or CNTB?

In the previous week, Connect Biopharma had 4 more articles in the media than AEON Biopharma. MarketBeat recorded 7 mentions for Connect Biopharma and 3 mentions for AEON Biopharma. AEON Biopharma's average media sentiment score of 1.06 beat Connect Biopharma's score of 0.36 indicating that AEON Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AEON Biopharma 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Connect Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is MREO or AEON more profitable?

AEON Biopharma's return on equity of 0.00% beat Mereo BioPharma Group's return on equity. Company Net Margins Return on Equity Return on Assets Mereo BioPharma Group N/A -74.82% -64.28% AEON Biopharma N/A N/A -994.63%

Does the media refer more to MREO or AEON?

In the previous week, Mereo BioPharma Group and Mereo BioPharma Group both had 3 articles in the media. AEON Biopharma's average media sentiment score of 1.06 beat Mereo BioPharma Group's score of 1.05 indicating that AEON Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mereo BioPharma Group 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AEON Biopharma 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, AEON or IMA?

ImageneBio is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AEON Biopharma N/A N/A -$36.63M -$4.42 N/A ImageneBio N/A N/A -$45.35M -$4.58 N/A

Is AEON or IMA more profitable?

AEON Biopharma's return on equity of 0.00% beat ImageneBio's return on equity. Company Net Margins Return on Equity Return on Assets AEON Biopharma N/A N/A -994.63% ImageneBio N/A -38.99% -34.84%

Does the media prefer AEON or IMA?

In the previous week, AEON Biopharma had 1 more articles in the media than ImageneBio. MarketBeat recorded 3 mentions for AEON Biopharma and 2 mentions for ImageneBio. ImageneBio's average media sentiment score of 1.38 beat AEON Biopharma's score of 1.06 indicating that ImageneBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AEON Biopharma 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImageneBio 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer INMB or AEON?

AEON Biopharma has a consensus price target of $1.67, suggesting a potential upside of 585.87%. Given AEON Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe AEON Biopharma is more favorable than INmune Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 AEON Biopharma 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75

Is INMB or AEON more profitable?

AEON Biopharma's return on equity of 0.00% beat INmune Bio's return on equity. Company Net Margins Return on Equity Return on Assets INmune Bio N/A -82.87% -62.23% AEON Biopharma N/A N/A -994.63%

Does the media refer more to INMB or AEON?

In the previous week, INmune Bio had 2 more articles in the media than AEON Biopharma. MarketBeat recorded 5 mentions for INmune Bio and 3 mentions for AEON Biopharma. AEON Biopharma's average media sentiment score of 1.06 beat INmune Bio's score of 0.65 indicating that AEON Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment INmune Bio 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AEON Biopharma 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate EXOZ or AEON?

AEON Biopharma has a consensus price target of $1.67, indicating a potential upside of 585.87%. Given AEON Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe AEON Biopharma is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score eXoZymes 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 AEON Biopharma 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75

Is EXOZ or AEON more profitable?

AEON Biopharma's return on equity of 0.00% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets eXoZymes N/A -292.15% -158.66% AEON Biopharma N/A N/A -994.63%

Does the media favor EXOZ or AEON?

In the previous week, AEON Biopharma had 1 more articles in the media than eXoZymes. MarketBeat recorded 3 mentions for AEON Biopharma and 2 mentions for eXoZymes. eXoZymes' average media sentiment score of 1.18 beat AEON Biopharma's score of 1.06 indicating that eXoZymes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment eXoZymes 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AEON Biopharma 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

AEON Biopharma (AEON) Competitors

$0.23 -0.01 (-4.53%)

Closing price 04:00 PM Eastern

Extended Trading

$0.24 +0.00 (+2.16%)

As of 07:30 PM Eastern

Compare

AEON vs. CNTB, MREO, IMA, INMB, and EXOZ

Should you buy AEON Biopharma stock or one of its competitors? AEON Biopharma's main competitors and comparable companies include Connect Biopharma (CNTB), Mereo BioPharma Group (MREO), ImageneBio (IMA), INmune Bio (INMB), and eXoZymes (EXOZ). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does AEON Biopharma compare to Connect Biopharma?

AEON Biopharma (NASDAQ:AEON) and Connect Biopharma (NASDAQ:CNTB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations.

In the previous week, Connect Biopharma had 4 more articles in the media than AEON Biopharma. MarketBeat recorded 7 mentions for Connect Biopharma and 3 mentions for AEON Biopharma. AEON Biopharma's average media sentiment score of 1.06 beat Connect Biopharma's score of 0.36 indicating that AEON Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AEON Biopharma	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Connect Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

AEON Biopharma presently has a consensus price target of $1.67, indicating a potential upside of 585.87%. Connect Biopharma has a consensus price target of $5.88, indicating a potential upside of 548.31%. Given AEON Biopharma's higher possible upside, research analysts plainly believe AEON Biopharma is more favorable than Connect Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AEON Biopharma	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

22.8% of AEON Biopharma shares are owned by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are owned by institutional investors. 9.4% of AEON Biopharma shares are owned by insiders. Comparatively, 22.6% of Connect Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

AEON Biopharma has higher earnings, but lower revenue than Connect Biopharma. Connect Biopharma is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AEON Biopharma	N/A	N/A	-$36.63M	-$4.42	N/A
Connect Biopharma	$60K	951.06	-$55.48M	-$1.19	N/A

AEON Biopharma has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market. Comparatively, Connect Biopharma has a beta of -0.16, indicating that its stock price is 116% less volatile than the broader market.

AEON Biopharma's return on equity of 0.00% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AEON Biopharma	N/A	N/A	-994.63%
Connect Biopharma	N/A	-165.41%	-121.58%

Summary

Connect Biopharma beats AEON Biopharma on 8 of the 14 factors compared between the two stocks.

How does AEON Biopharma compare to Mereo BioPharma Group?

Mereo BioPharma Group (NASDAQ:MREO) and AEON Biopharma (NASDAQ:AEON) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Mereo BioPharma Group presently has a consensus target price of $1.67, indicating a potential upside of 439.20%. AEON Biopharma has a consensus target price of $1.67, indicating a potential upside of 585.87%. Given AEON Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe AEON Biopharma is more favorable than Mereo BioPharma Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mereo BioPharma Group	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
AEON Biopharma	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

AEON Biopharma's return on equity of 0.00% beat Mereo BioPharma Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mereo BioPharma Group	N/A	-74.82%	-64.28%
AEON Biopharma	N/A	N/A	-994.63%

62.8% of Mereo BioPharma Group shares are owned by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are owned by institutional investors. 6.5% of Mereo BioPharma Group shares are owned by insiders. Comparatively, 9.4% of AEON Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

AEON Biopharma has lower revenue, but higher earnings than Mereo BioPharma Group. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mereo BioPharma Group	$500K	98.72	-$41.88M	-$0.04	N/A
AEON Biopharma	N/A	N/A	-$36.63M	-$4.42	N/A

In the previous week, Mereo BioPharma Group and Mereo BioPharma Group both had 3 articles in the media. AEON Biopharma's average media sentiment score of 1.06 beat Mereo BioPharma Group's score of 1.05 indicating that AEON Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mereo BioPharma Group	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AEON Biopharma	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mereo BioPharma Group has a beta of 0.2, meaning that its stock price is 80% less volatile than the broader market. Comparatively, AEON Biopharma has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market.

Summary

AEON Biopharma beats Mereo BioPharma Group on 8 of the 12 factors compared between the two stocks.

How does AEON Biopharma compare to ImageneBio?

AEON Biopharma (NASDAQ:AEON) and ImageneBio (NASDAQ:IMA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

AEON Biopharma's return on equity of 0.00% beat ImageneBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AEON Biopharma	N/A	N/A	-994.63%
ImageneBio	N/A	-38.99%	-34.84%

ImageneBio is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AEON Biopharma	N/A	N/A	-$36.63M	-$4.42	N/A
ImageneBio	N/A	N/A	-$45.35M	-$4.58	N/A

22.8% of AEON Biopharma shares are owned by institutional investors. Comparatively, 75.0% of ImageneBio shares are owned by institutional investors. 9.4% of AEON Biopharma shares are owned by insiders. Comparatively, 2.2% of ImageneBio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, AEON Biopharma had 1 more articles in the media than ImageneBio. MarketBeat recorded 3 mentions for AEON Biopharma and 2 mentions for ImageneBio. ImageneBio's average media sentiment score of 1.38 beat AEON Biopharma's score of 1.06 indicating that ImageneBio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AEON Biopharma	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ImageneBio	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AEON Biopharma presently has a consensus price target of $1.67, indicating a potential upside of 585.87%. ImageneBio has a consensus price target of $29.00, indicating a potential upside of 619.60%. Given ImageneBio's higher probable upside, analysts clearly believe ImageneBio is more favorable than AEON Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AEON Biopharma	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
ImageneBio	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25

AEON Biopharma has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market. Comparatively, ImageneBio has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market.

Summary

AEON Biopharma beats ImageneBio on 8 of the 14 factors compared between the two stocks.

How does AEON Biopharma compare to INmune Bio?

INmune Bio (NASDAQ:INMB) and AEON Biopharma (NASDAQ:AEON) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

AEON Biopharma's return on equity of 0.00% beat INmune Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-82.87%	-62.23%
AEON Biopharma	N/A	N/A	-994.63%

AEON Biopharma has a consensus price target of $1.67, suggesting a potential upside of 585.87%. Given AEON Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe AEON Biopharma is more favorable than INmune Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
AEON Biopharma	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

12.7% of INmune Bio shares are owned by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are owned by institutional investors. 21.4% of INmune Bio shares are owned by insiders. Comparatively, 9.4% of AEON Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, INmune Bio had 2 more articles in the media than AEON Biopharma. MarketBeat recorded 5 mentions for INmune Bio and 3 mentions for AEON Biopharma. AEON Biopharma's average media sentiment score of 1.06 beat INmune Bio's score of 0.65 indicating that AEON Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
INmune Bio	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AEON Biopharma	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AEON Biopharma has lower revenue, but higher earnings than INmune Bio. INmune Bio is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$50K	915.75	-$45.93M	-$0.67	N/A
AEON Biopharma	N/A	N/A	-$36.63M	-$4.42	N/A

INmune Bio has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market. Comparatively, AEON Biopharma has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market.

Summary

INmune Bio and AEON Biopharma tied by winning 7 of the 14 factors compared between the two stocks.

How does AEON Biopharma compare to eXoZymes?

eXoZymes (NASDAQ:EXOZ) and AEON Biopharma (NASDAQ:AEON) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

AEON Biopharma's return on equity of 0.00% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-292.15%	-158.66%
AEON Biopharma	N/A	N/A	-994.63%

22.8% of AEON Biopharma shares are held by institutional investors. 58.0% of eXoZymes shares are held by company insiders. Comparatively, 9.4% of AEON Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

eXoZymes has a beta of 3.19, indicating that its share price is 219% more volatile than the broader market. Comparatively, AEON Biopharma has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market.

In the previous week, AEON Biopharma had 1 more articles in the media than eXoZymes. MarketBeat recorded 3 mentions for AEON Biopharma and 2 mentions for eXoZymes. eXoZymes' average media sentiment score of 1.18 beat AEON Biopharma's score of 1.06 indicating that eXoZymes is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
eXoZymes	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AEON Biopharma	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AEON Biopharma has a consensus price target of $1.67, indicating a potential upside of 585.87%. Given AEON Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe AEON Biopharma is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
AEON Biopharma	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

eXoZymes has higher revenue and earnings than AEON Biopharma. eXoZymes is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eXoZymes	$70K	531.43	-$9.16M	-$1.19	N/A
AEON Biopharma	N/A	N/A	-$36.63M	-$4.42	N/A

Summary

eXoZymes beats AEON Biopharma on 7 of the 13 factors compared between the two stocks.

Get AEON Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AEON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AEON vs. The Competition

Export

Metric	AEON Biopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$11.57M	$3.97B	$7.44B	$12.94B
Dividend Yield	N/A	3.64%	2.50%	27.63%
P/E Ratio	1.29	9.68	192.52	18.55
Price / Sales	N/A	1,172.38	567.95	76.22
Price / Cash	N/A	122.10	76.54	51.88
Price / Book	-0.06	15.94	10.29	5.85
Net Income	-$36.63M	-$22.69M	$3.50B	$380.67M
7 Day Performance	-15.94%	-8.67%	-5.37%	-4.97%
1 Month Performance	-9.73%	-14.11%	-8.55%	-6.95%
1 Year Performance	-83.43%	0.66%	0.43%	-5.99%

AEON Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AEON AEON Biopharma	4.113 of 5 stars	$0.23 -4.5%	$1.67 +618.4%	-77.9%	$11.57M	N/A	1.29	8	Gap Down
CNTB Connect Biopharma	3.0751 of 5 stars	$0.91 +0.8%	$6.14 +578.5%	-51.5%	$57.02M	$2.95M	N/A	64
MREO Mereo BioPharma Group	3.6977 of 5 stars	$0.35 -9.8%	$1.67 +376.1%	-84.7%	$55.91M	N/A	N/A	39	Positive News Gap Down
IMA ImageneBio	3.3952 of 5 stars	$4.60 -2.2%	$29.00 +531.1%	-47.2%	$53.35M	N/A	N/A	18	Positive News Gap Up
INMB INmune Bio	0.4765 of 5 stars	$1.87 -3.6%	N/A	-14.5%	$51.90M	N/A	N/A	21	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AEON) was last updated on 10/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AEON Biopharma (AEON) Competitors

AEON vs. CNTB, MREO, IMA, INMB, and EXOZ

How does AEON Biopharma compare to Connect Biopharma?

Summary

How does AEON Biopharma compare to Mereo BioPharma Group?

Summary

How does AEON Biopharma compare to ImageneBio?

Summary

How does AEON Biopharma compare to INmune Bio?

Summary

How does AEON Biopharma compare to eXoZymes?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AEON vs. The Competition

AEON Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AEON Biopharma (AEON) Competitors

AEON vs. CNTB, MREO, IMA, INMB, and EXOZ

How does AEON Biopharma compare to Connect Biopharma?

Does the media prefer AEON or CNTB?

Do analysts rate AEON or CNTB?

Do insiders & institutionals believe in AEON or CNTB?

Which has higher valuation and earnings, AEON or CNTB?

Which has more volatility and risk, AEON or CNTB?

Is AEON or CNTB more profitable?

Summary

How does AEON Biopharma compare to Mereo BioPharma Group?

Do analysts rate MREO or AEON?

Is MREO or AEON more profitable?

Do institutionals and insiders have more ownership in MREO or AEON?

Which has better valuation & earnings, MREO or AEON?

Does the media refer more to MREO or AEON?

Which has more risk & volatility, MREO or AEON?

Summary

How does AEON Biopharma compare to ImageneBio?

Is AEON or IMA more profitable?

Which has preferable valuation and earnings, AEON or IMA?

Do institutionals & insiders believe in AEON or IMA?

Does the media prefer AEON or IMA?

Do analysts prefer AEON or IMA?

Which has more risk & volatility, AEON or IMA?

Summary

How does AEON Biopharma compare to INmune Bio?

Is INMB or AEON more profitable?

Do analysts prefer INMB or AEON?

Do insiders & institutionals hold more shares of INMB or AEON?

Does the media refer more to INMB or AEON?

Which has better earnings and valuation, INMB or AEON?

Which has more risk & volatility, INMB or AEON?

Summary

How does AEON Biopharma compare to eXoZymes?

Is EXOZ or AEON more profitable?

Do insiders and institutionals have more ownership in EXOZ or AEON?

Which has more risk & volatility, EXOZ or AEON?

Does the media favor EXOZ or AEON?

Do analysts rate EXOZ or AEON?

Which has higher valuation and earnings, EXOZ or AEON?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AEON vs. The Competition

AEON Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools